European biotech leaders split on US-China fight for deal dominance, survey finds
A BIO-Europe survey of 81 European biotech leaders, published Oct. 7, found no consensus on the top source of future innovation partnerships: 29 respondents picked the U.S., 24 picked China and 11 picked Europe. Europe received a "middling" score as a dealmaking hub, with capital availability named the biggest barrier to deals by 34 respondents and access to capital the top challenge to solve, cited by 42. Almost 80% blamed investor risk aversion for restricting investment.